Deutsche Bank Ag\ Fate Therapeutics Inc Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Deutsche Bank Ag\ holds 55,663 shares of FATE stock, worth $134,704. This represents 0.0% of its overall portfolio holdings.

Number of Shares

55,663

Previous 33,453 66.39%

Holding current value

$134,704

Previous $109,000 77.98%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$3.12 - $5.57 $69,295 - $123,709	22,210 Added 66.39%	55,663 $194,000
Q2 2024 Aug 14, 2024	SELL	$3.26 - $7.08 $21,284 - $46,225	-6,529 Reduced 16.33%	33,453 $109,000
Q1 2024 May 15, 2024	BUY	$3.54 - $8.35 $7,635 - $18,010	2,157 Added 5.7%	39,982 $293,000
Q4 2023 Feb 14, 2024	SELL	$1.65 - $3.94 $11,375 - $27,162	-6,894 Reduced 15.42%	37,825 $141,000
Q3 2023 Nov 09, 2023	SELL	$2.02 - $5.04 $405,436 - $1.01 Million	-200,711 Reduced 81.78%	44,719 $94,000
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $880,228 - $1.22 Million	184,922 Added 305.62%	245,430 $1.17 Million
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $734,240 - $1.93 Million	-173,170 Reduced 74.11%	60,508 $344,000
Q4 2022 Feb 13, 2023	BUY	$9.86 - $23.83 $105,245 - $254,361	10,674 Added 4.79%	233,678 $2.36 Million
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $1.79 Million - $3.06 Million	84,915 Added 61.49%	223,004 $5 Million
Q2 2022 Aug 11, 2022	SELL	$17.78 - $42.39 $191,046 - $455,480	-10,745 Reduced 7.22%	138,089 $3.42 Million
Q1 2022 May 13, 2022	SELL	$29.67 - $60.28 $107,642 - $218,695	-3,628 Reduced 2.38%	148,834 $5.77 Million
Q4 2021 Feb 11, 2022	SELL	$47.84 - $64.34 $31.4 Million - $42.2 Million	-656,148 Reduced 81.15%	152,462 $8.92 Million
Q3 2021 Nov 04, 2021	BUY	$59.27 - $95.73 $980,859 - $1.58 Million	16,549 Added 2.09%	808,610 $47.9 Million
Q2 2021 Aug 11, 2021	BUY	$67.25 - $92.52 $41.8 Million - $57.5 Million	620,999 Added 363.03%	792,061 $68.7 Million
Q1 2021 May 13, 2021	BUY	$72.16 - $117.4 $8.15 Million - $13.3 Million	112,930 Added 194.26%	171,062 $14.1 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $3.31 Million - $8.77 Million	-86,887 Reduced 59.91%	58,132 $5.29 Million
Q3 2020 Nov 12, 2020	SELL	$30.41 - $40.5 $5.92 Million - $7.88 Million	-194,622 Reduced 57.3%	145,019 $5.8 Million
Q2 2020 Aug 13, 2020	BUY	$20.21 - $35.23 $5.41 Million - $9.44 Million	267,825 Added 372.93%	339,641 $11.7 Million
Q1 2020 May 14, 2020	BUY	$17.28 - $31.88 $851,610 - $1.57 Million	49,283 Added 218.71%	71,816 $1.6 Million
Q4 2019 Feb 14, 2020	BUY	$13.39 - $20.73 $59,505 - $92,124	4,444 Added 24.57%	22,533 $440,000
Q3 2019 Nov 14, 2019	SELL	$15.47 - $22.5 $58,151 - $84,577	-3,759 Reduced 17.21%	18,089 $280,000
Q2 2019 Aug 14, 2019	SELL	$15.61 - $20.44 $1.56 Million - $2.04 Million	-99,792 Reduced 82.04%	21,848 $442,000
Q1 2019 May 15, 2019	BUY	$13.15 - $18.71 $1.25 Million - $1.77 Million	94,759 Added 352.51%	121,640 $2.14 Million
Q4 2018 Feb 14, 2019	SELL	$11.48 - $16.98 $2.11 Million - $3.12 Million	-183,691 Reduced 87.23%	26,881 $343,000
Q3 2018 Dec 21, 2021	BUY	$8.75 - $16.29 $666,286 - $1.24 Million	76,147 Added 56.65%	210,572 $3.43 Million
Q3 2018 Nov 14, 2018	BUY	$8.75 - $16.29 $325,841 - $606,623	37,239 Added 38.32%	134,425 $2.19 Million
Q2 2018 Apr 21, 2020	BUY	$9.16 - $13.48 $164,770 - $242,478	17,988 Added 22.71%	97,186 $1.1 Million
Q2 2018 Aug 14, 2018	BUY	$9.16 - $13.48 $127,424 - $187,520	13,911 Added 21.31%	79,198 $897,000
Q1 2018 Oct 18, 2019	BUY	$6.3 - $13.77 $85,969 - $187,905	13,646 Added 26.42%	65,287 $635,000
Q1 2018 May 15, 2018	SELL	$6.3 - $13.77 $219,807 - $480,435	-34,890 Reduced 40.32%	51,641 $502,000
Q4 2017 Feb 14, 2018	BUY	$3.94 - $6.64 $202,646 - $341,515	51,433 Added 146.54%	86,531 $527,000
Q3 2017 Nov 14, 2017	BUY	$2.6 - $4.31 $91,254 - $151,272	35,098	35,098 $138,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $235M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account